Abstract:OBJECTIVE:To investigate the roles of TNF-α, GSK-3β and RANKL in the occurrence and development of diabetic osteoporosis.METHODS:Diabetic rat model was established; tissue section technology was used to observe the situation of osteoporosis in diabetic rats; rat serum levels of OC, RANKL, GSK-3β, P38mapk, TNF-α and INS were detected by Elisa assay; osteoblasts and osteoclasts were primarily cultured and identified by immunohistochemistry and tartrate-resistant acid phosphatase (TRAP) staining respectively. The effects of GSK-3β inhibitors, lithium chloride, TNF-α antagonists and RANKL antagonists on the proliferation of osteoblasts and osteoclasts were evaluated; quantitative PCR was used to assess the effects of GSK-3β inhibitors, lithium chloride, on TNF-α and RANKL gene expression in osteoblasts and osteoclasts, and the effects of TNF-α and RANKL antagonists on GSK-3β gene expression in osteoblasts and osteoclasts.RESULTS:Diabetic rat model was successfully established; osteoblasts and osteoclasts were successfully isolated and cultured. Elisa experiments showed that in diabetic model group, the levels of RANKL, GSK-3β, P38mapk and TNF-α were significantly increased, while the levels of osteocalcin (OC) and insulin (INS) were significantly reduced; MTT results showed that osteoclast proliferation in GSK-3β inhibitor and lithium chloride groups were weaker than the untreated group, while osteoclast proliferation in TNF-α antagonist group and RANKL antagonist Group was very close to the untreated group. Osteoblast proliferation in GSK-3β inhibitor and lithium chloride groups were weaker than the untreated group, while osteoblast proliferation in TNF-α antagonist group and RANKL antagonist group was higher than the untreated group. In all of the corresponding groups, cell proliferation in the diabetic group was stronger than the untreated group. In GSK-3β inhibitor and lithium oxide groups, TNF-α and RANKL gene expression levels were elevated, but TNF-α and RANKL gene expression levels in the diabetic group were slightly lower than the control group. GSK-3β gene expression level in TNF-α antagonist group and RANKL antagonist group was reduced; GSK-3β gene expression level in diabetic group was lower than the control group.CONCLUSION:In diabetic rats, TNF-α, GSK-3β and RANKL levels were elevated; GSK-3β could promote the proliferation of osteoblasts and osteoclasts, and inhibit the expression of TNF-α and RANKL; TNF-α and RANKL can suppress the proliferation of osteoblasts while had little effect on osteoclast proliferation; they also can promote the GSK-3β gene expression; interactions between the three broke the balance between osteoblasts and osteoclasts, leading to osteoporosis.

Cereblon (CRBN) Deletion Reverses Streptozotocin Induced Diabetic Osteoporosis in Mice.

S6K/FLNC/ITGβ3 Signaling Pathway Regulates Osteoclastogenesis and the Inhibition of Osteoclastogenesis by Columbianadin

Cereblon regulates the production of hepatic fibroblast growth factor 23 in diabetes

Crif1 Promotes Osteoporosis in Mice after Radiation

Activation of BK channels prevents diabetes-induced osteopenia by regulating mitochondrial Ca2+ and SLC25A5/ANT2-PINK1-PRKN-mediated mitophagy

Cereblon Attenuates DNA Damage-Induced Apoptosis by Regulating the Transcription-Independent Function of P53

Cinnamaldehyde attenuates streptozocin-induced diabetic osteoporosis in a rat model by modulating netrin-1/DCC-UNC5B signal transduction

Zoledronate promotes osteoblast differentiation in high-glucose conditions via the p38MAPK pathway

Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes

RANKL/RANK contributes to the pathological process of type 2 diabetes mellitus through TRAF3 activation of NIK

The Ubiquitination-Dependent and -Independent Functions of Cereblon in Cancer and Neurological Diseases

FK506 prevented bone loss in streptozotocin-induced diabetic rats via enhancing osteogenesis and inhibiting adipogenesis

NLRP3 blockade by MCC950 suppressed osteoclastogenesis via NF-κB/c-FOS/NFATc1 signal pathway and alleviated bone loss in diabetes mellitus

Nε-Carboxymethyl-Lysine Mediates Vascular Calcification in Diabetes Caused by Impaired Osteoclastic Resorption Activity Through NFATc1-GNPTAB

Pathophysiological Mechanism of Bone Loss in Type 2 Diabetes Involves Inverse Regulation of Osteoblast Function by PGC-1α and Skeletal Muscle Atrogenes: AdipoR1 as a Potential Target for Reversing Diabetes-Induced Osteopenia

IGF-1R/-catenin signaling axis is implicated in streptozotocin exacerbating bone impairment in ovariectomized rats

Roles of TNF-α, GSK-3β and RANKL in the Occurrence and Development of Diabetic Osteoporosis.

Bavachinin selectively modulates PPAR γ and maintains bone homeostasis in Type 2 Diabetes

Osteoprotection Through the Deletion of the Transcription Factor Rorβ in Mice.

Inhibitory effects of high glucose/insulin environment on osteoclast formation and resorption in vitro

Activation of BK Channels Prevents Diabetes-Induced Osteopenia by Regulating Mitochondrial Ca 2+ and SLC25A5/ANT2-PINK1-PRKN-mediated Mitophagy